PF-4708671

For research use only. Not for use in humans.

Pfizer辉瑞授权生产 目录号：S2163

PF-4708671 Chemical Structure

CAS No. 1255517-76-0

PF-4708671是一种细胞渗透性p70 ribosomal S6 kinase(S6K1亚型)抑制剂，在无细胞试验中Ki/IC50为20 nM/160 nM，作用于S6K1比作用于S6K2选择性高400倍，作用于S6K1比作用于MSK1和RSK1/2选择性分别高4和20倍以上，是第一个报道的S6K1特异性抑制剂。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1574.66 现货
RMB 876.33 现货
RMB 1179.06 现货
RMB 2197.72 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的PF-4708671发表文献30篇：

产品安全说明书

S6 Kinase抑制剂选择性比较

生物活性

产品描述 PF-4708671是一种细胞渗透性p70 ribosomal S6 kinase(S6K1亚型)抑制剂，在无细胞试验中Ki/IC50为20 nM/160 nM，作用于S6K1比作用于S6K2选择性高400倍，作用于S6K1比作用于MSK1和RSK1/2选择性分别高4和20倍以上，是第一个报道的S6K1特异性抑制剂。
靶点
p70 S6K1 [1]
(Cell-free assay)
160 nM
体外研究

PF-4708671是一种哌嗪基嘧啶类似物，是第一个S6K1特异性抑制剂。PF-4708671不显著抑制紧密相关的S6K2亚型或一组其他AGC激酶 (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 或SGK1)的活性。PF-4708671抑制S6K1介导的响应IGF-1（胰岛素样生长因子1）的S6蛋白的磷酸化，对PMA-诱导的底物磷酸化没有作用效果，底物与RSK (p90核糖体S6激酶)和MSK（丝分裂原和应激活化蛋白激酶）激酶高度相关。PF-4708671诱导S6K1的T型环和疏水性基序磷酸化，这种作用依赖于mTORC1 (mTOR复合体1)。PF-4708671不影响mTORC1的活性。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 M37hVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULtbFRQUUN3ME2wMlgzODJ2IN88US=> M4jrXHNCVkeHUh?=
UACC-893 M2qxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTVwMUm4PFYh|ryP MYrTRW5ITVJ?
A427 NUDwZlRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\ONW5nUUN3ME21MlczPTZ5IN88US=> MnziV2FPT0WU
OCUB-M NWT2fnZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTZwNk[xNFIh|ryP NGTDU4xUSU6JRWK=
SW684 M2rFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHTO4tKSzVyPUeuOVIzPjhizszN NUXsPGpiW0GQR1XS
SK-LMS-1 NWrHbZpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DPOmlEPTB;OT6wNVMxOiEQvF2= MWrTRW5ITVJ?
CP50-MEL-B NGHoWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTlwM{C0NVkh|ryP MXLTRW5ITVJ?
NCI-H1651 M2WzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvPN2tEUUN3ME2xNE4xOjd4IN88US=> NEPpSXZUSU6JRWK=
ABC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml74TWM2OD1zMD6xNFM4KM7:TR?= NH7Nfo1USU6JRWK=
OE19 NICyfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvkXWdKSzVyPUGwMlE4OzNizszN M1zle3NCVkeHUh?=
DSH1 M3LKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFyLki4O|kh|ryP MWPTRW5ITVJ?
SW13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PZPWlEPTB;MUGuPVMyQSEQvF2= MVrTRW5ITVJ?
MDA-MB-453 NEP4T2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF{LkG2NFMh|ryP NHHFWmVUSU6JRWK=
647-V Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnFb4J5UUN3ME2xNk4{PTh{IN88US=> MmjxV2FPT0WU
NCI-H2342 NV\NfIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvt[VVpUUN3ME2xNk4{QTl3IN88US=> MoXuV2FPT0WU
LB2241-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF{LkW3O|kh|ryP MmLIV2FPT0WU
UACC-257 NXntSHAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITMS5ZKSzVyPUGzMlQ1PTNizszN Mm[xV2FPT0WU
NCI-H661 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fleWlEPTB;MUOuOlQ1QSEQvF2= NGLTR4RUSU6JRWK=
FADU NH\4[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn2VoJKSzVyPUGzMlY6QTJizszN Mn7jV2FPT0WU
A2780 M4\2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjRRm9KSzVyPUGzMlgxPDFizszN MmXqV2FPT0WU
NCI-H1793 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXZTWM2OD1zND60NFg2KM7:TR?= MojVV2FPT0WU
TE-8 M2nxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknuTWM2OD1zNT6zOFY2KM7:TR?= MoOxV2FPT0WU
HGC-27 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7lTWM2OD1zNj6xOlQ1KM7:TR?= NVniVmx{W0GQR1XS
MMAC-SF MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr0R2dzUUN3ME2xO{4{PzJ5IN88US=> M1fvO3NCVkeHUh?=
Calu-6 NID4V2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[4dVM2UUN3ME2xPE4yPTF|IN88US=> MlHYV2FPT0WU
HUTU-80 M1i0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXGTWM2OD1zOD6zPVU6KM7:TR?= NELQcGFUSU6JRWK=
SAS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjRS3ZKSzVyPUG4MlY1PTVizszN M{L3NnNCVkeHUh?=
IST-MES1 NGP4bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3NeZVKSzVyPUG4MlY2ODhizszN NYjGN442W0GQR1XS
C3A MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X4SWlEPTB;MUiuO|kyQSEQvF2= M4fxfnNCVkeHUh?=
ES3 M3y3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXhSppuUUN3ME2xPE45OzZ2IN88US=> MYnTRW5ITVJ?
HSC-2 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\hTWM2OD1zOT62OVQyKM7:TR?= MULTRW5ITVJ?
T47D NEWyPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJyLkG0PFUh|ryP NVjrWII{W0GQR1XS
EW-7 NEjMfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\kdZZKSzVyPUKwMlg2QDhizszN NYfqWIl6W0GQR1XS
LN-405 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H1RmlEPTB;MkCuPFk3PSEQvF2= MW\TRW5ITVJ?
U031 NHv0bYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3Ed2dKSzVyPUKxMlQ5ODJizszN Mn3kV2FPT0WU
A549 M{f1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITzT4NKSzVyPUKxMlg1QTFizszN NFz5VZFUSU6JRWK=
RMG-I NF76[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL2TWM2OD1{Mj6yOlY5KM7:TR?= MXrTRW5ITVJ?
BT-474 M4myUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;nfGlEPTB;MkKuOlU2OSEQvF2= MlPvV2FPT0WU
NB69 MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ|LkG1NkDPxE1? NIrtNHFUSU6JRWK=
NB7 NVPCcpd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnSSYpKSzVyPUK0MlE5QCEQvF2= NIC1Rm1USU6JRWK=
HCC1569 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ2Lk[xNlUh|ryP NIDkVnZUSU6JRWK=
MEL-JUSO MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jrOWlEPTB;MkSuOlkxQCEQvF2= M4i3VXNCVkeHUh?=
MDA-MB-175-VII M{i0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDBTWM2OD1{NT6yOVE4KM7:TR?= M2DCS3NCVkeHUh?=
HCC1419 NGX5SIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ3Lk[wNFMh|ryP NHLiT29USU6JRWK=
Ca9-22 M3G1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ3Lk[0N|Ih|ryP NHWwVVFUSU6JRWK=
KGN NUfvUYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC4PVdKSzVyPUK1Mlc2PDdizszN NVzncolKW0GQR1XS
LB373-MEL-D MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJ4LkG5N|gh|ryP NVLBZXp5W0GQR1XS
NCI-H1755 M33GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjnOYdTUUN3ME2yOk45QDRzIN88US=> NFL6[m1USU6JRWK=
D-423MG M3\td2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MliyTWM2OD1{Nz6wO|E2KM7:TR?= MojJV2FPT0WU
DK-MG M1qxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH6TWM2OD1{OD63PFQ3KM7:TR?= MofEV2FPT0WU
NCI-H1623 NUL6b|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3tT5lKSzVyPUK4Mlg{PDJizszN MXTTRW5ITVJ?
KU-19-19 NVPMS2lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLRTWM2OD1{OD65PVUh|ryP MUnTRW5ITVJ?
C-33-A NUn5W4tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDMUoNLUUN3ME2yPU4zOTl6IN88US=> MnL1V2FPT0WU
SCC-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXnTWM2OD1|MD6zN|U1KM7:TR?= MoT5V2FPT0WU
MG-63 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfWXGlKSzVyPUOwMlU6QTRizszN NYfJOnEzW0GQR1XS
LNCaP-Clone-FGC NHjUbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrtPY9KSzVyPUOxMlQ6OjFizszN NIXsXYpUSU6JRWK=
CAPAN-1 NVfGeXZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNzLkWyPFYh|ryP MYDTRW5ITVJ?
GI-ME-N NVTmfZU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LmbmlEPTB;M{GuOVM2OyEQvF2= NYrNb|Z5W0GQR1XS
RERF-LC-MS NE\Nc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvYVFRKSzVyPUOyMlY4PDdizszN MXXTRW5ITVJ?
KLE M3XwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjIfYxKSzVyPUOzMlQ{OzRizszN NXrmR25FW0GQR1XS
KNS-81-FD NYHqcHlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHEVJFRUUN3ME2zN{42ODB6IN88US=> MlHGV2FPT0WU
DOK MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLxTWM2OD1|ND62OlEzKM7:TR?= Ml\LV2FPT0WU
ACHN Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTN3LkG1PFgh|ryP MoTiV2FPT0WU
KYSE-520 M4nEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7QUZA6UUN3ME2zOU4zOzZzIN88US=> MXjTRW5ITVJ?
SBC-5 NFrCRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN3LkWxNVYh|ryP NHrmbnlUSU6JRWK=
NCI-H28 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi1c5NXUUN3ME2zOU43Pjl3IN88US=> MYrTRW5ITVJ?
ES7 NFvBZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN4LkKyOFkh|ryP NHTJSJlUSU6JRWK=
A172 M4TGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme0TWM2OD1|Nj60NVg4KM7:TR?= MYjTRW5ITVJ?
UM-UC-3 M3fkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLDbmMyUUN3ME2zO{45PzR4IN88US=> NXLr[3h4W0GQR1XS
LXF-289 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPqTWM2OD1|OD6wNFQ4KM7:TR?= MUDTRW5ITVJ?
KP-4 M3jLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OyTmlEPTB;M{iuOFc{QSEQvF2= MVzTRW5ITVJ?
TE-1 NVf6O|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW2TWM2OD1|OT62OVg6KM7:TR?= M2i2V3NCVkeHUh?=
G-402 NXLm[4ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn70TWM2OD12MD6wOlEh|ryP NWHm[Jh7W0GQR1XS
786-0 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HIdGlEPTB;NECuPVA6PiEQvF2= MYTTRW5ITVJ?
K5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHxbIFKSzVyPUSxMlM3QDZizszN NV:wR|ljW0GQR1XS
SK-N-DZ NEHLdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRzLkO4NlMh|ryP MUnTRW5ITVJ?
OVCAR-4 NIflXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XlUGlEPTB;NEGuO|U3QCEQvF2= M4\UbXNCVkeHUh?=
T84 M4f0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXK[ZZUUUN3ME20Nk4yOjZ|IN88US=> NULNRXoyW0GQR1XS
GCIY NIT2ZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTR|LkC4NFMh|ryP M4DQc3NCVkeHUh?=
BB49-HNC MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXVTWM2OD12Mz6zN|Q5KM7:TR?= MmP0V2FPT0WU
SNU-C2B NUDzU3dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm5TWM2OD12Mz62OFM3KM7:TR?= NFi3eZBUSU6JRWK=
TE-6 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTR|Lki4PVQh|ryP Mo\rV2FPT0WU
23132-87 NWL1TIlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTR2LkK5O|gh|ryP M2ntN3NCVkeHUh?=
DMS-53 NGnJRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrab3FKSzVyPUS0MlM{QDRizszN MnLYV2FPT0WU
ONS-76 M3jxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PtNmlEPTB;NESuO|Y3OSEQvF2= NUXGT49zW0GQR1XS
DMS-273 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHaO3VKSzVyPUS0Mlk1OyEQvF2= NVjvUnJvW0GQR1XS
COLO-824 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG2TWM2OD12NT64O|c2KM7:TR?= NH30PYRUSU6JRWK=
DMS-114 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD6[4Q3UUN3ME20OU45QTJ5IN88US=> MnuzV2FPT0WU
YKG-1 NEHKPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTGcm44UUN3ME20Ok4xOzV3IN88US=> MUHTRW5ITVJ?
RH-18 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyzTWM2OD12Nj6zO|M{KM7:TR?= MXvTRW5ITVJ?
NCI-H1355 NEnXSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofxTWM2OD12Nj62NVgh|ryP NIDPT2lUSU6JRWK=
NCI-H2170 NFfjV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvSTWM2OD12Nz63OVg1KM7:TR?= MknyV2FPT0WU
OC-314 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP0[4xPUUN3ME20O{45PDd6IN88US=> MUfTRW5ITVJ?
NCI-H2030 NFzWdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHexc4ZKSzVyPUS3Mlg6ODZizszN M{DVOnNCVkeHUh?=
22RV1 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:zTWM2OD12Nz65NFE2KM7:TR?= MmHjV2FPT0WU
G-401 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR6LkS0NVUh|ryP MXrTRW5ITVJ?
YAPC NHX6OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTrTWM2OD12OT64NFc{KM7:TR?= MXjTRW5ITVJ?
SW1573 NYDrTm1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm2SZY{UUN3ME21NE4zPDN3IN88US=> MnHEV2FPT0WU
COLO-792 NYXLfZFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3mN5ZKUUN3ME21NE43OjN5IN88US=> MXXTRW5ITVJ?
KNS-62 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTVyLke1NFgh|ryP NWfyT3lqW0GQR1XS
NB5 NFnMe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DqcGlEPTB;NUGuOFUxQSEQvF2= NIfINpJUSU6JRWK=
CP66-MEL NVTKfHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLyXYpKSzVyPUWxMlY1ODhizszN M1PMc3NCVkeHUh?=
CaR-1 NXXuSZpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv5TWM2OD13Mj6wOlA3KM7:TR?= NVvhW5p{W0GQR1XS
CAL-54 NH35RYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr5UmdGUUN3ME21Nk4yOTB{IN88US=> Mn3tV2FPT0WU
8305C NIP0S4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfWTWM2OD13Mj6zNVUh|ryP NWPu[ZlrW0GQR1XS
Calu-3 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjZbXh1UUN3ME21Nk4{PzN|IN88US=> M3nNVHNCVkeHUh?=
AU565 M1KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K3NWlEPTB;NUKuOVUxQSEQvF2= NYnJT4xGW0GQR1XS
CW-2 NF7CTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TQeGlEPTB;NUKuPFY2PCEQvF2= MUfTRW5ITVJ?
BEN NV3pO4Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjxRoI1UUN3ME21N{44QDZ{IN88US=> NWPPPXF1W0GQR1XS
NCI-H1975 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTV|Lki5OlYh|ryP Mn3NV2FPT0WU
HCT-116 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTV2LkCzNlch|ryP NVvacZBCW0GQR1XS
SH-4 M1v2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH3XZpqUUN3ME21OE4yOzhizszN M4\YZXNCVkeHUh?=
NCI-H1693 NX;QSGNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTV2LkKxNFMh|ryP Mn;OV2FPT0WU
BPH-1 MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\JTWM2OD13NT6yPFkzKM7:TR?= NVjMT4VsW0GQR1XS
CAMA-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jMeGlEPTB;NUWuPFEyPiEQvF2= Ml7FV2FPT0WU
A388 NYrWXlBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHTZYlXUUN3ME21Ok4xQTh3IN88US=> MYfTRW5ITVJ?
C2BBe1 M2O4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33tSGlEPTB;NU[uNlY{PCEQvF2= MXfTRW5ITVJ?
GAMG NG\FUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\V[JRGUUN3ME21Ok42QTV3IN88US=> MkDXV2FPT0WU
MKN28 NFqwXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml60TWM2OD13Nj64NFE{KM7:TR?= MV\TRW5ITVJ?
VA-ES-BJ MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTV4Lki3OFUh|ryP NF31UG5USU6JRWK=
HuCCT1 NYfRRoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33kUmlEPTB;NUeuNFQ6OiEQvF2= MkPoV2FPT0WU
BFTC-905 M3HsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi0fZpKSzVyPUW3MlI5QThizszN MVfTRW5ITVJ?
LS-123 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnkdWhKSzVyPUW3MlU3PjhizszN NEniZZJUSU6JRWK=
LB996-RCC Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTOdXI2UUN3ME21PE4xOjh5IN88US=> MmHSV2FPT0WU
NCI-H1048 M1nmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTV6LkKxPFgh|ryP NH3NWFJUSU6JRWK=
COR-L105 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mySmlEPTB;NUiuO|M{PyEQvF2= NUDaOoVDW0GQR1XS
OVCAR-8 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInFdWhKSzVyPUW5MlE4OTZizszN MlzCV2FPT0WU
SK-N-FI M3e0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPoNlZXUUN3ME21PU4{OjB5IN88US=> NYXnSXdZW0GQR1XS
MES-SA MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTV7LkS1NFkh|ryP NWOyeld7W0GQR1XS
SCC-9 NH\TOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHSVpJKSzVyPUW5MlQ4PTNizszN MkfIV2FPT0WU
EFO-27 NVnHVWxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK1TWM2OD13OT65OFMh|ryP NVvPbnRwW0GQR1XS
GT3TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\PTWM2OD14MD62NFQ5KM7:TR?= MojSV2FPT0WU
HCC38 NWHi[2xGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e2T2lEPTB;NkGuOFM4QSEQvF2= NWDS[WVuW0GQR1XS
MLMA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vocGlEPTB;NkGuOlE3OyEQvF2= MYHTRW5ITVJ?
D-566MG NFLMcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZ|LkWyNlQh|ryP MULTRW5ITVJ?
SF295 NFfteplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLZTWM2OD14Mz62OlU2KM7:TR?= MVrTRW5ITVJ?
ES4 NXvpWFg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLvNpZKSzVyPU[0MlQ4OTlizszN NVnre|JxW0GQR1XS
CAKI-1 NVHZV|RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofWTWM2OD14ND61O|IyKM7:TR?= MlOwV2FPT0WU
OAW-28 M{Kxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknNTWM2OD14ND65OlQ4KM7:TR?= MoLaV2FPT0WU
NCI-H460 NXjsbI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXQT3MzUUN3ME22OU4xQDl5IN88US=> NITLVVlUSU6JRWK=
JAR NIHLfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPKd5J[UUN3ME22OU42PTF4IN88US=> M4m4VnNCVkeHUh?=
SNU-449 NXLIOGZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XFbGlEPTB;NkWuO|YyPiEQvF2= NX;pNIlmW0GQR1XS
D-392MG M16yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TmcGlEPTB;NkWuPVQ{PCEQvF2= NHj3UmhUSU6JRWK=
EW-22 MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrJTWM2OD14Nj6zPVUh|ryP MYfTRW5ITVJ?
GCT MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf0c2NPUUN3ME22O{4xPDR|IN88US=> NI[xd5BUSU6JRWK=
NOS-1 M1;JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\LdGlEPTB;NkeuOlg3PyEQvF2= MkfpV2FPT0WU
RH-1 MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;SPWlEPTB;NkiuOVU2QSEQvF2= MVXTRW5ITVJ?
HuH-7 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTZ7LkGwNFIh|ryP MmC2V2FPT0WU
NUGC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW3SHd5UUN3ME23NE46PjR2IN88US=> M2DyOXNCVkeHUh?=
IST-SL1 NEHFSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTdzLkKzNlQh|ryP NXS3dIhFW0GQR1XS
SHP-77 NX\4fJM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPJTWM2OD15Mj6xNVkh|ryP M3m0XHNCVkeHUh?=
SW1116 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\ITWM2OD15Mj6xOFA4KM7:TR?= MVvTRW5ITVJ?
LK-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\nbI5KSzVyPUeyMlg3OTJizszN MX;TRW5ITVJ?
U-2-OS MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fPRWlEPTB;N{OuNVgzQCEQvF2= M4GwSnNCVkeHUh?=
KYSE-150 NEfTUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXraR5ZMUUN3ME23N{43OTF6IN88US=> NInWdWFUSU6JRWK=
U251 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPDcIRHUUN3ME23N{45OTZ6IN88US=> NWC5WmVQW0GQR1XS
HT-1080 NFTtSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTWTWM2OD15ND6yOVc1KM7:TR?= MlqxV2FPT0WU
NCI-H1437 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\BWmlEPTB;N{SuOlMzPiEQvF2= NFroSoNUSU6JRWK=
HPAF-II MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:wTWM2OD15ND62OFE2KM7:TR?= NGPxUpdUSU6JRWK=
Becker NXzI[Xo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTd3LkGxNFUh|ryP MYnTRW5ITVJ?
PANC-10-05 M1fWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3kdZpKSzVyPUe1MlI5PjVizszN MojMV2FPT0WU
TYK-nu MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDr[nFNUUN3ME23OU4{OTB{IN88US=> NYflZVB{W0GQR1XS
SKG-IIIa MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILmW2JKSzVyPUe1MlM{PDFizszN NXrRb4lYW0GQR1XS
NCI-H1993 NX7Nb3RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrPZVhKSzVyPUe1Mlc{QTdizszN NUTZXnFWW0GQR1XS
S-117 M2KyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXB[oh4UUN3ME23OU44PTVizszN MUjTRW5ITVJ?
HuO9 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDsTWM2OD15Nj6wNFQ5KM7:TR?= NEPt[4tUSU6JRWK=
CAL-51 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTd4LkGwNFYh|ryP M360O3NCVkeHUh?=
BT-20 M3vjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnhTWM2OD15Nj6yNVY5KM7:TR?= NGLsSXBUSU6JRWK=
LB831-BLC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;LTWM2OD15Nj6zNlE4KM7:TR?= MkKzV2FPT0WU
LB1047-RCC NIXUVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXeyc|lsUUN3ME23Ok44PjF7IN88US=> M1\wfnNCVkeHUh?=
ES8 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3sTWM2OD15OD6wNFc{KM7:TR?= MYPTRW5ITVJ?
UMC-11 NVmxc5hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHzTWM2OD15OD6wPFg1KM7:TR?= NET3[5hUSU6JRWK=
NCI-H226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPzTWM2OD15OD6xN|E2KM7:TR?= NFvIUHpUSU6JRWK=
IGROV-1 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fRTGlEPTB;N{iuOVU2KM7:TR?= NFixW|NUSU6JRWK=
BHY NIH3VZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTd7LkW5OkDPxE1? MkD2V2FPT0WU
MKN45 NXHDZXM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTwTopCUUN3ME24NE4{OTd2IN88US=> M2TJWXNCVkeHUh?=
IA-LM NHSxd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;QNGI2UUN3ME24NE4{PTFzIN88US=> NVy2e2JOW0GQR1XS
WM-115 Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfHTWM2OD16MT60NVE1KM7:TR?= MVjTRW5ITVJ?
VMRC-RCZ NILkfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRThzLkS0NlUh|ryP M2TsbXNCVkeHUh?=
NCI-H2291 NXX4OW06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3jbVBZUUN3ME24NU43QDR{IN88US=> NGXTd3pUSU6JRWK=
MCF7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqxTWM2OD16Mz6yPFk4KM7:TR?= NYjGNIdWW0GQR1XS
639-V M3vlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICxOHVKSzVyPUi0MlYyOjlizszN MXXTRW5ITVJ?
RT4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTh3LkK0NFMh|ryP MkXhV2FPT0WU
NCI-H2405 M4PUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH3bZNKSzVyPUi1MlI6QTdizszN NX\aR|k3W0GQR1XS
CAL-33 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn6VWo4UUN3ME24OU43OzF3IN88US=> M1;NOXNCVkeHUh?=
BT-549 M2rXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfnRm1KSzVyPUi1Mlk{QDJizszN MoPoV2FPT0WU
HT-1197 NFPTRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HvSGlEPTB;OEiuNVA4PyEQvF2= NXnFSIVZW0GQR1XS
G-361 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml24TWM2OD16OD6xOFc1KM7:TR?= NXX5W5dIW0GQR1XS
LS-411N NEewR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr3enRKSzVyPUi5MlM{QDhizszN Mkj1V2FPT0WU
HT-144 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTh7LkW5PVIh|ryP NV;aUIdwW0GQR1XS
DJM-1 NYn4UpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXuTWM2OD16OT64PFQ2KM7:TR?= NVHrXZBQW0GQR1XS
CAL-12T MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPYUWExUUN3ME25NE44QDl3IN88US=> MUjTRW5ITVJ?
MKN7 NYrHRWk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTlzLkO1OVEh|ryP NW\XPWlPW0GQR1XS
HuP-T3 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrRTWM2OD17Nj6xNFA1KM7:TR?= NHnnZ4FUSU6JRWK=
SK-MG-1 M2\BNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TIXGlEPTB;OU[uNVM1QCEQvF2= NYjzWGppW0GQR1XS
NCI-H2347 NXvScG9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\yR2RZUUN3ME25PE4yODR{IN88US=> MofiV2FPT0WU
SW872 NIruOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jQT2lEPTB;MUCwMlQ2PiEQvF2= NGq2SHpUSU6JRWK=
COLO-829 NWe4XXU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHsfHcxUUN3ME2xNFAvPTV|IN88US=> NYqzUpFZW0GQR1XS
MC-IXC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0VWlEPTB;MUCwMlYyPSEQvF2= M2XUVnNCVkeHUh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

28626016 30423811
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
30% PEG400+0.5% Tween80+5% propylene glycol
 30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 390.41
化学式

C19H21F3N6
CAS号 1255517-76-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • 回答：

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

Selleck产品目录册

S6 Kinase Signaling Pathway Map

相关S6 Kinase产品

  • LY2584702 New

    LY2584702是一种选择性的，ATP竞争性的p70S6K抑制剂，IC50为4 nM。Phase 1。

  • LY2584702 Tosylate New

    LY2584702 Tosylate是一种选择性的，ATP竞争性p70S6K抑制剂，IC50为 4 nM。Phase 1。

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021)是一种GSK-3α和GSK-3β抑制剂， IC50分别为10 nM and 6.7 nM。CHIR99201对CDKs没有交叉反应性，对GSK-3β的选择性是对CDKs选择性的350倍。CHIR-99021 可作为Wnt/β-catenin的激活剂并诱导自噬。

  • BI-D1870

    BI-D1870是一种ATP-竞争性S6 ribosome抑制剂，在无细胞试验中作用于RSK1/2/3/K4，IC50分别为31 nM/24 nM/18 nM/15 nM，作用于RSK比作用于MST2，GSK-3β，MARK3，CK1和Aurora B选择性高10到100倍。BI-D1870 显示除了抗癌的属性包括活性氧的生成、提高内质网应激反应和诱导自噬。

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus, AY 22989, NSC-2260804)是一种特定的 mTOR 抑制剂，在 HEK293细胞中，IC50 为 ~0.1 nM。

  • MK-2206 2HCl

    MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂，在无细胞试验中IC50分别为8 nM/12 nM/65 nM；对250种其他蛋白激酶没有抑制活性。MK-2206 2HCl 在肿瘤细胞中可诱导自噬和凋亡。Phase 2。

    Features:MK-2206是第一个进入临床研究阶段的Akt小分子变构抑制剂。

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl是CHIR-99021的盐酸盐, 是GSK-3α/β抑制剂，IC50为10 nM/6.7 nM。其对GSK-3的选择性比对Cdc2和ERK2高500倍以上。CHIR-99021 是一种有效的药理性的 Wnt/beta-catenin 信号通路的激活剂。CHIR-99021 可显著地拯救光诱导的 autophagy，并可增强 GR，RORα和自噬相关蛋白等表达。

  • LY294002

    LY294002 (SF 1101, NSC 697286) 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。LY294002 可以抑制CK2，对应的IC50值为98 nM。LY294002 是一种非特异的 DNA-PKcs 抑制剂，并可激活自噬和凋亡。

    Features:LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA, NSC 66389) 是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。3-Methyladenine (3-MA)可成功应用于抑制线粒体自噬。现配现用（加热助溶）。

  • Everolimus (RAD001)

    Everolimus (RAD001)是一种mTOR抑制剂，作用于FKBP12，在无细胞试验中IC50为1.6-2.4 nM。Everolimus 可诱导细胞凋亡及自噬并抑制肿瘤细胞的增殖。

Tags: 购买PF-4708671 | PF-4708671供应商 | 采购PF-4708671 | PF-4708671价格 | PF-4708671生产 | 订购PF-4708671 | PF-4708671代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID